Accuray Inc.’s (NASDAQ:ARAY) recent agreement with RaySearch Laboratories around an extended alliance, is a major step toward online adaptive radiation therapy. The integration of Accuray’s imaging technology and photon-based radiation therapy platforms with RaySearch’s proprietary planning and workflow solutions, will fast-track innovation across the space. For Accuray, the arrangement will also accelerate its adoption to online procedures, while remaining focused on its core strengths around treatment delivery and imaging.
Extended Collaboration Meets a Transformation Plan Ahead of Target
The collaboration would allow Accuray to leverage RaySearch’s expertise in system and software integrations, to offer more personalized treatments. With an initial focus on the company’s Radixact system, the coverage will be extended across Accuray’s other platforms such as the CyberKnife.
In line with the agreement, Accuray has agreed to purchase specified RayStation licenses with a total order value of $8 million, following which the two companies will work together for commercialization of online adaptive radiation therapy platforms. The partnership also integrates RayCare technology to simplify connectivity among clinical systems, and RaySearch will continue refining its software specifically for integration with the Radixact platform.
The deal builds upon the ongoing momentum from Accuray’s transformation plan, which the management highlighted in its recent Q4 FY26 results announcement. So far, the plan has delivered cost and margin improvements in excess of $20 million for fiscal 2026, compared with its original $12 million target.
The Underlying Swing Factors
Several underlying risk factors could temper the optimism around this collaboration. Adoption risk will be one major concern, as online adaptive radiation therapies require substantial amount of investments from clinics in infrastructure upgrades, advanced workflows, and trainings. Following Accuray’s $8 million investment in license purchases, the revenue impact could get limited in case healthcare providers exhibit slow adoption.
Another key consideration is the third-party dependency for a strategic initiative of this scale. A lot rests on RaySearch’s smooth execution of the required software development and integration work. Any disruptions could lead to delays in Accuray’s plans for expansion of these adaptive therapy offerings, as well as potential extension to other platforms further down the line. It could result in adverse implications for Accuray’s competitive position and growth path across the radiation therapy market.
Institutional Sentiment
Institutional data tracked across 1,000+ hedge funds by Insider Monkey reveals an increasing number of smart money managers invested in the company. As per 13F filing data for Q2 2026, a total of 13 hedge funds held positions in the stock compared to 11 by the end of the first quarter. Short Interest of 3.91% shows limited amount of active betting against the stock.
As per Yahoo Finance database, TCW Group is the largest institutional investor with 18.94 million shares, representing 15.86% of outstanding shares. Other notable institutional names include Neuberger Berman Group and Armistice Capital that hold 5.09% and 4.80% of outstanding shares, respectively.
Verdict
An extended collaboration with RaySearch solidifies Accuray’s position across its extensive global service network and installed base. This could potentially boost adoption of its various platforms. Ultimately, this arrangement advances Accuray’s broader growth strategy by allowing it to deliver efficient and personalized therapies to clinics and patients globally.
READ NEXT: 12 Best Industrial Stocks With More Than 50% Upside and 10 Best Stocks Under $10 That Could Triple.
Hedge Fund Resource Center